Johnson & Johnson (NYSE: JNJ) recently reported its Q3 results, with revenues and earnings exceeding our estimates.
Johnson & Johnson reported better-than-expected third-quarter sales and raised its full-year revenue guidance.
Johnson & Johnson's Q3 2024 results surpassed analyst expectations, reporting $2.42 EPS and $22.47 billion in sales. Updated ...
Though psoriasis affects people of all skin tones, that diversity isn’t always represented in portrayals of the condition in ...
A Springfield resident and local real estate entrepreneur, Evan Plotkin has just been awarded $15 million after a jury found ...
David Risinger, an analyst from Leerink Partners, maintained the Buy rating on Johnson & Johnson (JNJ – Research Report). The ...
This season could be Flau'jae Johnson's last at LSU. Here's what the star junior thinks about her WNBA draft eligibility.
History will be in the air in New Orleans on Thursday night as the Saints honor Drew Brees during their game against the ...
Johnson & Johnson (JNJ – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...
Naturally, much of the near 10-minute discussion was focused on the defense and its struggles. Just one year after leading ...
A jury in Bridgeport awarded the money to a man who reportedly developed mesothelioma because of asbestos in Johnson & ...